Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15306535 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
Condition: Tuberculosis
Interventions: Drug: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid;   Drug: Isoniazid, Rifampin, Pyrazinamide, Ethambutol

Indicates status has not been verified in more than two years